Dr. Elisa Ignatius, MD, MS

Dr. Ignatius practices at Johns Hopkins Bayview Medical Center in Baltimore, Maryland, part of Johns Hopkins Health System.

Dr. Ignatius' NPI, 1871936583, was assigned on April 11, 2013. Dr. Ignatius graduated from Emory University School of Medicine in 2013. Dr. Ignatius holds Maryland license D86142.

Dr. Ignatius' primary practice is Johns Hopkins Bayview Medical Center, at 4940 Eastern Avenue, Baltimore, MD 21224 in Baltimore City. The practice phone is (410) 550-0123.

Dr. Ignatius' primary practice is Johns Hopkins Bayview Medical Center in Baltimore, Maryland, part of Johns Hopkins Health System. Dr. Ignatius is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Ignatius to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ignatius practices, 5 sites in all. Vendor and product names are available with a free account.

Infectious disease is Dr. Ignatius' primary specialty in the NPI Registry, under taxonomy code 207RI0200X. Dr. Ignatius is licensed in Maryland.

CMS data shows 329 Medicare services from Dr. Ignatius across 7 procedure codes in 2024, for 124 Medicare patients. Medicare paid $23,809 for them.

CMS counts 124 Medicare patients who saw Dr. Ignatius in 2024. The largest group is 65 to 74, with 53 patients. 73% of them have copd, and 71% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ignatius' median patient age at 71, with 77% women.

In 2024, Dr. Ignatius wrote 417 Medicare Part D claims for 51 patients. 69% of them were for generic drugs. CMS names the drug for 313 of them, across 10 drugs with 11 or more claims each, at $1,233,135 in total drug cost. In 2023, CMS named 181 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Ignatius for performance year 2024, reported as part of a group. CMS lists Dr. Ignatius as offering telehealth.

Dmand AI links 21 papers to Dr. Ignatius, published from 2014 to 2025. 2020 was the busiest year, with 3. The most frequent topics are Antitubercular Agents, Isoniazid and Tuberculosis, Multidrug-Resistant. Dr. Ignatius has published most often in Am J Respir Crit Care Med. Dr. Ignatius' most frequent co-authors are Eric Lee Nuermberger, MD, Richard Hafner, MD and Daniel Belz, MD.

CMS Open Payments shows 2 general payments to Dr. Ignatius from 1 drug or device company in 2022. Food and beverage make up the largest share, 100% of the total. Insmed, Inc. paid the most, $43.

Dr. Ignatius graduated from Emory University School of Medicine in 2013.